ClinicalTrials.gg

Program

ammoxetine

Also written as “Ammoxetine hydrochloride enteric-coated tablets”, “Ammoxetine” and “ammoxetine hydrochloride enteric-coated tablets”.

Its studies are mostly in Depressive Disorder, Major · Depression, led by CSPC Pharmaceutical Group.

Furthest: phase 3, since Dec 30, 202410 company-led studies, 3 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSPC Pharmaceutical Group103 open or runningphase 3since Dec 30, 2024Aug 9, 2017none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 9, 2017First study: phase 1 study in DepressionFirst studyNCT03456388 · 58 enrolled · China
  2. Feb 20, 2019Phase 1 study in DepressionNCT03850834 · 36 enrolled
  3. Jul 30, 2021Phase 2 study in Depressive Disorder, MajorNCT05018013 · 240 enrolled · China
  4. Jan 28, 2023Phase 2 study in Depressive Disorder, MajorNCT05762458 · 240 enrolled
  5. Dec 30, 2024Phase 3 study in Depressive Disorder, MajorNCT06827431 · 786 enrolled · China
  6. Mar 24, 20262 phase 1 studies in Healthy ParticipantsNCT07508501, NCT07508462
  7. Jul 2, 20263 phase 1 studies in Healthy ParticipantsNCT07756996, NCT07694869, NCT07694843

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07694869Healthy Participants · China1RecruitingOct 10, 202616
NCT07694843Healthy Participants · China1RecruitingOct 31, 202624
NCT07756996Healthy Participants · China1RecruitingAug 31, 202662
NCT07508501Healthy Participants · China1CompletedFeb 24, 202314
NCT07508462Healthy Participants · China1CompletedJun 17, 202418
NCT06827431Depressive Disorder, Major · China3CompletedJul 14, 2026786
NCT05762458Depressive Disorder, Major2UNKNOWNMay 15, 2024240
NCT05018013Depressive Disorder, Major · China2UNKNOWNAug 1, 2022240
NCT03850834Depression1UNKNOWNMay 31, 201936
NCT03456388Depression · China1CompletedJul 11, 201858

How it is read

Names in the registry

  • “Ammoxetine hydrochloride enteric-coated tablets”, 6 entries
  • “Ammoxetine”, 3 entries
  • “ammoxetine hydrochloride enteric-coated tablets”, 2 entries
  • “Ammoxetine Hydrochloride Enteric-coated Tablets”, 2 entries
  • “Ammoxetine hydrochloride Enteric-coated Tablets(new formulation)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.